Search results for: Iva Gunnarsson

Items from 1 to 20 out of 33 results

article

Strong Association of Combined Genetic Deficiencies in the Classical Complement Pathway With Risk of Systemic Lupus Erythematosus and Primary Sjögren's Syndrome

Christian Lundtoft, Christopher Sjöwall, Solbritt Rantapää‐Dahlqvist, Anders A. Bengtsson, more

Arthritis & Rheumatology > 74 > 11 > 1842 - 1850

Objective Complete genetic deficiency of the complement component C2 is a strong risk factor for monogenic systemic lupus erythematosus (SLE), but whether heterozygous C2 deficiency adds to the risk of SLE or primary Sjögren's syndrome (SS) has not been studied systematically. This study was undertaken to investigate potential associations of heterozygous C2 deficiency and C4 copy number variation...

article

Complement C4 Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases

Christian Lundtoft, Pascal Pucholt, Myriam Martin, Matteo Bianchi, more

Arthritis & Rheumatology > 74 > 8 > 1440 - 1450

Objective Copy number variation of the C4 complement components, C4A and C4B, has been associated with systemic inflammatory autoimmune diseases. This study was undertaken to investigate whether C4 copy number variation is connected to the autoimmune repertoire in systemic lupus erythematosus (SLE), primary Sjögren's syndrome (SS), or myositis. Methods Using targeted DNA sequencing, we determined...

article

Contribution of Rare Genetic Variation to Disease Susceptibility in a Large Scandinavian Myositis Cohort

Matteo Bianchi, Sergey V. Kozyrev, Antonella Notarnicola, Lina Hultin Rosenberg, more

Arthritis & Rheumatology > 74 > 2 > 342 - 352

Objective Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of complex autoimmune conditions characterized by inflammation in skeletal muscle and extramuscular compartments, and interferon (IFN) system activation. We undertook this study to examine the contribution of genetic variation to disease susceptibility and to identify novel avenues for research in IIMs. Methods Targeted...

article

Proteinase 3 Autoreactivity in Anti‐Neutrophil Cytoplasmic Antibody–associated vasculitis—Immunological versus clinical features

Ravi K. Sharma, Björn Lövström, Iva Gunnarsson, Vivianne Malmström

Scandinavian Journal of Immunology > 92 > 5 > n/a - n/a

ANCA‐associated vasculitis (AAV) is a group of chronic inflammatory diseases of small‐ and medium‐sized vessels, which are broadly subdivided based on organ manifestations and disease‐specific autoantibodies. The so called anti‐neutrophil cytoplasmic antibodies (ANCA) mostly target one of the enzymes, proteinase 3 (PR3) or myeloperoxidase (MPO). Accumulating genetic data demonstrates that these two...

article

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

Azita Sohrabian, Ioannis Parodis, Nellie Carlströmer-Berthén, Martina Frodlund, more

Arthritis Research & Therapy > 2019 > 21 > 1 > 1-15

Introduction Immune complexes are of importance in systemic lupus erythematosus pathogenesis, and autoantibodies are believed to participate in immune complex formation. Quantification of autoantibody levels in circulating IC might be of prognostic value. Methods A C1q-binding-eluting technique was applied to purify immune complexes from 55 belimumab-treated systemic lupus erythematosus patients...

article

The Impact of Belimumab and Rituximab on Health‐Related Quality of Life in Patients With Systemic Lupus Erythematosus

Ioannis Parodis, Angie H. Lopez Benavides, Agneta Zickert, Susanne Pettersson, more

Arthritis Care & Research > 71 > 6 > 811 - 821

Objective Accumulating evidence supports an impaired health‐related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE). We investigated the effects of 2 biologic treatments on HRQoL of patients with SLE. Methods Patients with SLE from the Karolinska University Hospital treated with belimumab (n = 34) or rituximab (n = 35) were included; normative values derived from Swedish...

article

High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus

Vilija Oke, Iva Gunnarsson, Jessica Dorschner, Susanna Eketjäll, more

Arthritis Research & Therapy > 2019 > 21 > 1 > 1-11

Background and aim Interferons (IFNs) are considered to be key molecules in the pathogenesis of systemic lupus erythematosus (SLE). We measured levels of type I, II and III IFNs in a large cohort of patients with systemic lupus erythematosus (SLE) and controls and explored associations among high levels of different IFN types and distinct SLE features. Methods Four hundred ninety-seven well-characterized...

article

Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives

Helena Idborg, Arash Zandian, Ann-Sofi Sandberg, Bo Nilsson, more

Arthritis Research & Therapy > 2019 > 21 > 1 > 1-11

Background Previous studies and own clinical observations of patients with systemic lupus erythematosus (SLE) suggest that SLE harbors distinct immunophenotypes. This heterogeneity might result in differences in response to treatment in different subgroups and obstruct clinical trials. Our aim was to understand how SLE subgroups may differ regarding underlying pathophysiology and characteristic biomarkers...

article

Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus

Jonas Carlsson Almlöf, Sara Nystedt, Dag Leonard, Maija-Leena Eloranta, more

Human Genetics > 2019 > 138 > 2 > 141-150

Systemic lupus erythematosus (SLE, OMIM 152700) is a systemic autoimmune disease with a complex etiology. The mode of inheritance of the genetic risk beyond familial SLE cases is currently unknown. Additionally, the contribution of heterozygous variants in genes known to cause monogenic SLE is not fully understood. Whole-genome sequencing of DNA samples from 71 Swedish patients with SLE and their...

article

Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis

Uta Hardt, Anders Larsson, Iva Gunnarsson, Robert M. Clancy, more

Arthritis Research & Therapy > 2018 > 20 > 1 > 1-12

Background Immunoglobulin M (IgM) autoreactivity to malondialdehyde (MDA) protein modifications is part of the natural antibody repertoire in health and may have beneficial functions. In contrast, IgG anti-MDA are increased in chronic inflammation and autoimmunity and may instead have pathogenic properties. Methods Herein, we investigated serum IgG anti-MDA levels by enzyme-linked immunosorbent...

article

Multivariate strategy for the sample selection and integration of multi-batch data in metabolomics

Izabella Surowiec, Erik Johansson, Frida Torell, Helena Idborg, more

Metabolomics > 2017 > 13 > 10 > 1-12

Introduction Availability of large cohorts of samples with related metadata provides scientists with extensive material for studies. At the same time, recent development of modern high-throughput ‘omics’ technologies, including metabolomics, has resulted in the potential for analysis of large sample sizes. Representative subset selection becomes critical for selection of samples from bigger cohorts...

article

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)

Vilija Oke, Susanna Brauner, Anders Larsson, Johanna Gustafsson, more

Arthritis Research & Therapy > 2017 > 19 > 1 > 1-12

Background Interferon (IFN)-α is thought to have a pivotal role in systemic lupus erythematosus (SLE), and type III IFNs (IFN-λ) were recently also associated with SLE. In this study, we measured levels of IFN-α, IFN-λ1, and related cytokines, such as IL-17A, IL-23, and interferon-γ-induced protein 10 (IP-10), in a Karolinska University Hospital cohort of patients with SLE and control subjects. The...

article

Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis

Laurent Arnaud, Annica Nordin, Hannes Lundholm, Elisabet Svenungsson, more

Arthritis & Rheumatology > 69 > 6 > 1272 - 1279

Objective Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are autoimmune diseases that predominantly affect female patients, and therefore fewer investigations have been conducted in men. The aim of this study was to analyze sex hormone levels in male patients with SLE and those with SSc, compared to matched controls, in relation to the use of corticosteroids and cyclophosphamide...

article

Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis

Federico Alberici, Rona M. Smith, Mariana Fonseca, Lisa C. Willcocks, more

Journal of Allergy and Clinical Immunology > 2017 > 139 > 5 > 1684-1687.e10

article

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus

Ioannis Parodis, Christopher Sjöwall, Andreas Jönsen, Daniel Ramsköld, more

Autoimmunity Reviews > 2017 > 16 > 4 > 343-351

Belimumab is the first biologic drug approved for Systemic Lupus Erythematosus (SLE). Here, we aimed to investigate the effects of belimumab on clinical and serologic outcomes, and sought to identify predictors of treatment response in three Swedish real-life settings.Fifty-eight patients were enrolled at initiation of belimumab and followed longitudinally for up to 53months. Surveillance outcomes...

article

Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts

Andreas Jönsen, Frida Hjalte, Minna Willim, Katarina Steen Carlsson, more

Seminars in Arthritis and Rheumatism > 2016 > 45 > 6 > 684-690

The main objectives of this study were to calculate total costs of illness and cost-driving disease features among patients with systemic lupus erythematosus (SLE) in Sweden.Five cohorts of well-defined SLE patients, located in different parts of the country were merged. Incident and prevalent cases from 2003 through 2010 were included. The American College of Rheumatology (ACR) classification criteria...

article

Decreased levels of autoantibodies against apolipoprotein B‐100 antigens are associated with cardiovascular disease in systemic lupus erythematosus

Elisabet Svenungsson, Daniel Engelbertsen, Maria Wigren, Johanna T Gustafsson, more

Clinical & Experimental Immunology > 181 > 3 > 417 - 426

Increased production of autoantibodies is a characteristic feature of systemic lupus erythematosus (SLE) and there is evidence that several of these autoantibodies may contribute to increased cardiovascular disease (CVD) in SLE. Autoantibodies against the apolipoprotein (apo) B‐100 peptides p45 and p210 have been associated with a lower CVD risk in non‐SLE cohorts. The aim of the present study was...

article

IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment

Agneta Zickert, Petra Amoudruz, Yvonne Sundström, Johan Rönnelid, more

BMC Immunology > 2015 > 16 > 1 > 1-10

Background Recent studies indicate a central role for the IL-23/IL-17 axis in the pathogenesis of lupus nephritis (LN) but the importance in the context of treatment outcome is unknown. We studied various cytokines, including the IL-23/IL-17 axis, in association to histopathology and response to therapy. Methods Fifty-two patients with active LN were included. Renal biopsies were performed at baseline...

article

Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up

Jakob Gerhardsson, Birgitta Sundelin, Agneta Zickert, Leonid Padyukov, more

Arthritis Research & Therapy > 2015 > 17 > 1 > 1-9

Introduction Renal involvement is a severe complication in systemic lupus erythematosus (SLE). Moreover, a subset of SLE patients develop the anti-phospholipid syndrome (APS), characterised by the occurrence of anti-phospholipid antibodies in combination with macro- and microvascular thrombotic manifestations, including acute and chronic antiphospholipid-associated nephropathy (APLN). Clinical presentations...

article

Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus

Lina Wirestam, Hanna Schierbeck, Thomas Skogh, Iva Gunnarsson, more

Arthritis Research & Therapy > 2015 > 17 > 1 > 1-10

Introduction The non-histone nuclear protein high mobility group box protein-1 (HMGB1) is typically associated with nucleosomes, but may shuttle between the nucleus and the cytoplasm, and under some conditions also be released extracellularly and participate in systemic inflammation. Monoclonal HMGB1-targeting antibodies can ameliorate murine polyarthritis and lupus-like disease. Interestingly, autoantibodies...

Publication date

Last 3 years (3)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

INFONA - science communication portal

Search results for: Iva Gunnarsson

Strong Association of Combined Genetic Deficiencies in the Classical Complement Pathway With Risk of Systemic Lupus Erythematosus and Primary Sjögren's Syndrome

Complement C4 Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases

Contribution of Rare Genetic Variation to Disease Susceptibility in a Large Scandinavian Myositis Cohort

Proteinase 3 Autoreactivity in Anti‐Neutrophil Cytoplasmic Antibody–associated vasculitis—Immunological versus clinical features

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

The Impact of Belimumab and Rituximab on Health‐Related Quality of Life in Patients With Systemic Lupus Erythematosus

High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus

Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren’s syndrome differ in molecular signatures and treatment perspectives

Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus

Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis

Multivariate strategy for the sample selection and integration of multi-batch data in metabolomics

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)

Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis

Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus

Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts

Decreased levels of autoantibodies against apolipoprotein B‐100 antigens are associated with cardiovascular disease in systemic lupus erythematosus

IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment

Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up

Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus

Filter options

Publication date

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Iva Gunnarsson

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options